New crystal forms of oxcarbazepine and processes for their preparation
CA 2437402 A1 · Owner: Teva Pharmaceutical Industries, Ltd. · Inventors: Dolitzky, Ben-Zion; Garth, Nissim; Aronhime, Judith
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides for new crystal forms of oxcarbazepine more , particularly oxcarbazepine Forms B C, D and E. The present invention further provides processes for preparation of these forms. Form B is prepared by evaporating the solvents from a solution of oxcarbazepine in toluene and dichloromethane. Form B is also obtained by immediately cooling the solution of oxcarbazepine and toluene. Cooling the same solution at a slower rate but , still fairly rapidly, results in oxcarbazepine Form C. Cooling th same solution at even a slower rate results in another Form oxcarbazepine Form D. , Oxcarbazepine Form E a solvate of chloroform, is obtained by precipitating a solution …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 12, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 12, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 12, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.